Expert Comparison Guide: Choosing the Right Medication Class
ADHD medications fall into two main categories: stimulants and non-stimulants. Understanding the differences is crucial for choosing the right treatment.
| Feature | Stimulants | Non-Stimulants |
|---|---|---|
| Examples | Adderall, Vyvanse, Ritalin, Concerta, Focalin, Dexedrine | Strattera, Intuniv, Kapvay, Qelbree |
| Mechanism | Increase dopamine/norepinephrine rapidly | Modulate norepinephrine gradually (Strattera, Qelbree) or affect prefrontal cortex (Intuniv, Kapvay) |
| Response Rate | 70-80% | 50-60% |
| Effect Size | Large (d = 0.9-1.0) | Medium (d = 0.6-0.7) |
| Time to Effect | 30-120 minutes (immediate) | 2-6 weeks (gradual) |
| Duration | 4-14 hours (depending on formulation) | 24 hours |
| Schedule | Schedule II (controlled substance) | Not controlled (except Qelbree - Schedule IV) |
| Abuse Potential | Yes (moderate-high) | Minimal to none |
| Common Side Effects | Appetite loss, insomnia, increased HR/BP, anxiety | Sedation, nausea, dry mouth, constipation |
| Cardiac Concerns | More significant (HR/BP elevation) | Less significant (Intuniv may lower BP) |
| Can Take "As Needed" | Yes | No (must take daily) |
| Cost (Generic) | $20-$80/month | $30-$200/month (Strattera, Intuniv generic; Qelbree expensive) |
| First-Line Treatment | ✅ Yes (AAP, AACAP guidelines) | ❌ Second-line (unless contraindication to stimulants) |
All major ADHD treatment guidelines (American Academy of Pediatrics, American Academy of Child & Adolescent Psychiatry) recommend stimulants as first-line pharmacotherapy because:
How they work: Block reuptake of dopamine and norepinephrine in synaptic cleft
Medications:
Advantages: Shorter half-life (may have less impact on sleep/appetite), less cardiovascular effect than amphetamines
How they work: Block reuptake AND promote release of dopamine/norepinephrine
Medications:
Advantages: Longer duration, may be more effective for some patients, smoother extended-release profiles (especially Vyvanse)
Non-stimulants are FDA-approved for ADHD but typically used as second-line treatment (after stimulants) or first-line in specific situations (see "When to Use Non-Stimulants" section).
Medication: Strattera (atomoxetine) - first non-stimulant FDA-approved for ADHD (2002)
How it works: Selectively blocks reuptake of norepinephrine in prefrontal cortex, improving attention and impulse control
Key Features:
Best for:
Side effects: Nausea (first 1-2 weeks), dry mouth, decreased appetite, fatigue, sexual dysfunction (adults), rare liver toxicity (black box warning)
Contraindications: MAOIs, narrow-angle glaucoma, severe cardiac disease
Medications: Intuniv (guanfacine XR) and Kapvay (clonidine XR)
How they work: Stimulate alpha-2A receptors in prefrontal cortex, improving working memory, attention, and impulse control
Key Features:
Best for:
Side effects: Sedation (common, especially first 2-3 weeks), low blood pressure, dizziness, dry mouth, constipation, rebound hypertension if stopped abruptly
Important: Cannot stop abruptly - must taper slowly to avoid rebound hypertension
Medication: Qelbree (viloxazine ER) - newest non-stimulant, FDA-approved 2021
How it works: Blocks reuptake of norepinephrine and (to lesser extent) dopamine, also modulates serotonin
Key Features:
Best for:
Side effects: Somnolence (common), decreased appetite, fatigue, nausea, headache. Black box warning for suicidal ideation in children/adolescents (monitor closely first 2 months)
Note: Very expensive (~$400-500/month), no generic until 2030s
Multiple large meta-analyses consistently show stimulants are more effective than non-stimulants for ADHD:
| Study | Findings |
|---|---|
| Cortese et al. (2018) Lancet Psychiatry |
• Network meta-analysis of 133 RCTs, 10,068 children/adolescents • Methylphenidate most effective (effect size: 0.78) • Amphetamines second (effect size: 0.79) • Non-stimulants lower: Atomoxetine (0.56), Guanfacine (0.63) |
| Faraone & Buitelaar (2010) Neuropsychopharmacology |
• Stimulants: effect size d = 0.9-1.0 (large) • Atomoxetine: effect size d = 0.7 (medium) • Stimulants ~30% more effective than non-stimulants |
| Cunill et al. (2016) European Psychiatry |
• Atomoxetine efficacy in adults: effect size 0.45 • Significantly lower than stimulants (d = 0.8-1.0) • But atomoxetine better tolerated (fewer dropouts) |
This algorithm reflects evidence-based guidelines from AAP, AACAP, and clinical practice:
Start with Non-Stimulants First-Line If:
Clinical Picture: 24-year-old with ADHD and past cocaine use disorder, now 2 years sober
Recommendation: Start with Strattera or Qelbree
Rationale: No abuse potential, cannot be diverted. If inadequate response, can cautiously try Vyvanse (lowest abuse potential stimulant due to prodrug design)
Clinical Picture: 16-year-old with ADHD and GAD, stimulant trial worsened anxiety significantly
Recommendation: Strattera or Intuniv
Rationale: Both can improve anxiety while treating ADHD. Intuniv particularly good if sleep problems also present
Clinical Picture: 10-year-old with ADHD and motor/vocal tics worsened by methylphenidate
Recommendation: Intuniv or Kapvay (first choice), or Strattera
Rationale: Alpha-2 agonists can actually improve tics while treating ADHD. Treats both conditions
Clinical Picture: College student needs ADHD symptom control through evening study sessions (9pm-midnight)
Recommendation: Combination: Long-acting stimulant + Strattera
Rationale: Strattera provides 24-hour baseline coverage. Stimulant for peak daytime effect. Avoids late-day stimulant dose that disrupts sleep
Clinical Picture: 45-year-old with ADHD, hypertension (140/90), and family history of early MI
Recommendation: Strattera or Intuniv (if BP remains elevated)
Rationale: Strattera has minimal cardiovascular effects. Intuniv can actually lower blood pressure. Avoid stimulants or use with cardiology clearance and close monitoring
Clinical Picture: 8-year-old on Vyvanse, lost 12 lbs (10% body weight) over 4 months despite dietary interventions
Recommendation: Switch to Intuniv or Strattera
Rationale: Non-stimulants have less appetite suppression. Can also consider stimulant "drug holidays" on weekends, but non-stimulant switch often preferable
Clinical Picture: Adult tried methylphenidate (multiple formulations) and amphetamines (multiple formulations) at adequate doses - partial response only
Recommendation: Add Strattera or Intuniv to stimulant (combination therapy)
Rationale: Combination often more effective than either alone. Targets different neurotransmitter systems
Many patients ultimately benefit from combining stimulant + non-stimulant medications:
Dr. Sultan provides comprehensive ADHD medication management in NYC. With 15+ years specializing in ADHD and 411-cited research on ADHD medications, he can help you navigate stimulant vs non-stimulant options and find your optimal treatment.
Request ADHD Consultation📍 Location: Columbia University Medical Center, NYC
Stimulants first (unless contraindicated). They're more effective (70-80% vs 50-60% response rates), work immediately, and have the most evidence. Start with non-stimulants if you have: substance use history, cardiac concerns, severe anxiety, or tics worsened by stimulants.
Possibly. About 25-30% of stimulant non-responders will respond to non-stimulants. They work through different mechanisms, so failure of one doesn't predict failure of the other.
Yes, very commonly. Combination therapy (stimulant + non-stimulant) is well-studied and often more effective than either alone. Common combinations: stimulant + Intuniv, or stimulant + Strattera.
Different safety profiles, not necessarily "safer." Non-stimulants avoid: appetite suppression, insomnia, cardiovascular effects, abuse potential. But they have their own risks: sedation, nausea, rebound hypertension (alpha-2 agonists), liver toxicity (Strattera - rare), suicidal ideation (Qelbree - monitored).
Efficacy trumps side effects in first-line choice. Untreated ADHD has serious consequences (academic failure, job loss, accidents, relationship problems). Stimulants give the best chance of symptom control. We use non-stimulants when stimulants aren't appropriate or didn't work.
At least 4-6 weeks at therapeutic dose. Unlike stimulants (which work immediately), non-stimulants take 2-6 weeks to build effect. Don't give up after 1 week - give it adequate time.
No. Non-stimulants must be taken daily for continuous effect. Stopping them results in loss of benefit. Alpha-2 agonists (Intuniv, Kapvay) must be tapered - stopping abruptly can cause dangerous rebound hypertension.
Yes. Non-stimulants (except Qelbree) are not controlled substances and have minimal to no abuse potential. This makes them safer for patients with substance use history or in situations where diversion is a concern (college, adolescents).
Dr. Ryan Sultan is an Assistant Professor of Clinical Psychiatry at Columbia University and a leading ADHD researcher. His 2019 JAMA study on ADHD medications has been cited 411+ times and informed FDA policy on ADHD treatment.
Dr. Sultan's ADHD Medication Expertise: